The site for prostate cancer information
from Dr. William Catalona
William J. Catalona, MD
Our goal is to provide information on the latest advances in prostate cancer treatment and information on the research and work of Dr. William J. Catalona, Medical Director of the Urological Research Foundation (URF).
Dr. Catalona developed the PSA test as a screening test for prostate cancer. He and his research collaborators continue their important work.
The funds and energies of the Urological Research Foundation (URF) are directed to research for the prevention, detection, treatment and cure of the diseases of the prostate and most specifically, prostate cancer.
Dr. Catalona is one of the first surgeons to perform and perfect nerve sparing surgery in radical prostatectomy operations. Dr. Catalona has performed more than 6,000 radical prostatectomies.
Early Treatment of Prostate Cancer
The Early Treatment of Prostate Cancer video explains the issues associated with the treatment of early prostate cancer. This video is for men who have been recently diagnosed with prostate cancer and are trying to weigh the various treatment options.
Search QUEST articles using the search box at the top of the page.
Dr. Catalona Receives National Physician of the Year Award
On March 21, Dr. William Catalona received a 2016 Castle Connolly National Physician of the Year Award for Clinical Excellence in New York City. Each year, Castle Connolly Medical Ltd. recognizes both physicians and leaders in health care whose dedication, talents and skills have improved the lives of people throughout the world.
Watch the video introducing Dr. Catalona at the awards ceremony below.
Understanding Research and Treatment News:
A Virtual Town Meeting for Advanced Prostate Cancer Patients and Their Loved Ones
On April 10, 2016, Dr. Catalona participated in Understanding Research and Treatment News: A Virtual Town Meeting for Advanced Prostate Cancer Patients and Their Loved Ones. The webinar featured leading experts discussing the latest research and treatment information, inspirational patient stories and advice for living well.
The National Cancer Institute awarded Dr. Catalona and his colleagues a grant of approximately $11 million over 5 years for the Prostate SPORE (Specialized Program of Research Excellence). Learn more about the award in the Summer/Fall 2015 issue of Quest and the research projects in the Winter 2014 issue of QUEST. SPOREs are an integral part of the National Cancer Institute’s efforts to promote collaborative and interdisciplinary cancer research.
The funding of the SPORE is a cause for celebration. It will enable researchers to conduct studies that impact the outcomes and quality of life of prostate cancer patients.
Prostate Cancer World Congress
Dr. Catalona attended the 2015 Prostate Cancer World Congress in Australia.
WGN News Features PHI Test
The Prostate Health Index (PHI) test is now available at Northwestern Memorial Hospital, offering patients a new option for detecting prostate cancer. In February, WGN News highlighted the PHI test and interviewed Dr. Catalona in a story entitled “New test means new way to fight prostate cancer.”
Alert: New Concerns Revealed about Robotic Surgery
FDA Surveying Hospitals and Surgeons about Robotic Surgery Complications
The FDA is investigating the safety of surgical robots used in many US hospitals for surgery. By surveying surgeons at key hospitals, the government agency seeks to determine if the rise in incidents, including deaths, reported to the FDA result from the robots or from other issues.
The Large Urology Group Practice Association (LUGPA) released its prostate cancer screening guidelines in response to the recent PSA controversy, saying that data clearly demonstrates that are detecting prostate cancer earlier and thus saving lives.
The LUGPA's position on PSA screening is:
Risks of prostate cancer screening must be uncoupled from risks of prostate cancer detection and treatment
PSA testing facilitates the early detection of prostate cancer, which results in a reduced risk of being diagnosed with or developing locally advanced and/or metastatic prostate cancer, and a reduction in prostate cancer-specific mortality
A baseline PSA level should be obtained in men in their 40s who have made an informed decision to pursue early detection of prostate cancer
Intervals for an individual's prostate cancer screening should be adapted to: baseline PSA, prostate cancer risk factors (including African-American heritage and a family history of prostate cancer), and the potentially short preclinical timeline of aggressive cancers
PSA screening should be offered to men with a life expectancy of greater than or equal to 10 years, regardless of age
PSA testing should not be considered on its own, but rather as part of a multivariable approach to early prostate cancer detection
LUGPA is an organization advocating for integrated and coordinated urological care with more than 2,000 physician experts across the U.S. The association represents 121 large urology group practices in the United States, with more than 2,000 physicians who make up more than 20% of the nation’s practicing urologists.
International Prostate Cancer Research Group Receives Funding
The International Consortium for Prostate Cancer Genetics (ICPCG) received a grant for its important genetic research. Specifically, the ICPCG whole exome sequence project will receive funding. The results of this project could be incorporated in Dr. Catalona’s SPORE (Specialized Program of Research Excellence) proposal to discover genetic variants associated with the aggressive types of prostate cancer that lead to the failure of active surveillance.
The ICPCG is a collaborative group conducting research on familial prostate cancer. The researchers in this group share a common interest in genetic susceptibility for prostate cancer. Dr. Catalona is a principal investigator of the Northwestern University site of the ICPCG.
This section includes articles to help you understand the disturbing ramifications of the recent USPSTF recommendation on PSA testing, the misinterpretation of studies, and what can be done to ensure men have a choice in taking the test. We also provide information on contacting your government representatives.
"PSA is the best screening test we have for prostate cancer, and until there is a replacement for PSA, it would be unconscionable to stop it. Contrary to the USPSTF report, compelling evidence shows that PSA screening reduces prostate cancer deaths. This evidence needs to be shared with the public."
Healthcare decisions are as much about the future as the present, and they need to be based upon accurate and reliable information.
Participate in Research Studies
Northwestern Memorial Hospital and Dr. William Catalona offer opportunities for you to participate in research projects on the treatment and prevention of prostate cancer.
Dr. Catalona is celebrating a surgical anniversary. He has now performed more than 7,000 radical prostatectomies, more than anyone else in the world. Dr. Catalona is one of the first surgeons to perform and perfect nerve- sparing surgery in radical prostatectomy operations. His patients have come from all 50 states in the United States, as well as from Asia, Europe, the Middle East, and Central and South America.
High Ranking For Northwestern’s Department of Urology
The National Institutes of Health (NIH) ranks individual departments within medical schools. The Department of Urology ranked third nationally among urology departments.
Contact Dr. Catalona
William J. Catalona, M.D.
Professor, Department of Urology
Northwestern University Feinberg School of Medicine
Director, Clinical Prostate Cancer Program
Robert H. Lurie Comprehensive Cancer Center
Northwestern Memorial Hospital
675 North St. Clair Street
Chicago, Illinois 60611
Phone: (312) 695-4471
Dr. Catalona's nurse's phone: (312) 695-6174
FAX (312) 695-3070
To schedule surgery, please contact
Dr. Catalona at (312) 695-4471 or via email at firstname.lastname@example.org or email@example.com.
Scheduling a return appointment: (312) 695-8146
Scheduling a new patient appointment: (312) 695-4471